2025 is a truly pivotal year, expected to end with the commercialization of our first AI-based Software as a Medical Device, ...

Advanced non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the world. Epidermal growth factor receptor (EGFR) is expressed in 50% of NSCLCs, and its expression is ...

Up to €37.5m of Median’s funding comes from the EIB, and €10m from an equity line with IRIS Capital Investment.